SEC Company Response from VERTEX PHARMACEUTICALS (VRTX) — Jul 11, 2016
VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: July 11, 2016 · CIK: 0000875320 · Accession: 0000875320-16-000085
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Referenced dates: June 30, 2016
Letter
Document
VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE • BOSTON, MA 02210-1862
TEL. 617-341-6100 • http://www.vrtx.com
July 11, 2016
Delivered via EDGAR
Securities and Exchange Commission Division of Corporation Finance
100 First Street, N.E.
Mail Stop 4720
Washington, DC 20549
Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant
Re: Vertex Pharmaceuticals Incorporated
Form 10-K for the Fiscal Year Ended December 31, 2015
Filed February 16, 2016
File No. 000-19319
Ladies and Gentlemen:
The purpose of this letter is to confirm receipt of comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) to Vertex Pharmaceuticals Incorporated (the “Company”) set forth in the Staff’s letter to Jeffrey M. Leiden, dated June 30, 2016 (the “Comment Letter”), regarding the Company’s Form 10-K for the fiscal year ended December 31, 2015.
Based on the Company’s conversation with Ms. Bonnie Baynes, Staff Accountant for the Commission, with your permission the Company hereby agrees to submit its response to the Comment Letter no later than August 12, 2016. The Company plans to use this extra time to more thoroughly address the Staff’s comments.
Please contact me at (617) 961-7018 if you have any questions or concerns with respect to this matter.
Very truly yours,
/s/ Michael J. LaCascia
Show Raw Text
CORRESP 1 filename1.htm Document VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE • BOSTON, MA 02210-1862 TEL. 617-341-6100 • http://www.vrtx.com July 11, 2016 Delivered via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 First Street, N.E. Mail Stop 4720 Washington, DC 20549 Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Vertex Pharmaceuticals Incorporated Form 10-K for the Fiscal Year Ended December 31, 2015 Filed February 16, 2016 File No. 000-19319 Ladies and Gentlemen: The purpose of this letter is to confirm receipt of comments from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) to Vertex Pharmaceuticals Incorporated (the “Company”) set forth in the Staff’s letter to Jeffrey M. Leiden, dated June 30, 2016 (the “Comment Letter”), regarding the Company’s Form 10-K for the fiscal year ended December 31, 2015. Based on the Company’s conversation with Ms. Bonnie Baynes, Staff Accountant for the Commission, with your permission the Company hereby agrees to submit its response to the Comment Letter no later than August 12, 2016. The Company plans to use this extra time to more thoroughly address the Staff’s comments. Please contact me at (617) 961-7018 if you have any questions or concerns with respect to this matter. Very truly yours, /s/ Michael J. LaCascia Michael J. LaCascia Senior Vice President and General Counsel